Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Travera Inc
Seagen Inc.
KaliVir Immunotherapeutics
iOnctura
Sotio Biotech Inc.
Ohio State University
Endeavor Biomedicines, Inc.
University of Nebraska
Novartis
Kezar Life Sciences, Inc.
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
Incyte Corporation
Actym Therapeutics, Inc.
Incyte Corporation
Azienda Ospedaliera di Padova
Incyte Corporation
University of Pittsburgh
Turnstone Biologics, Corp.